Trial Profile
Prospective Open-Label Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Pulmonary alveolar proteinosis
- Focus Therapeutic Use
- 26 Sep 2023 Status changed from recruiting to completed.
- 22 Oct 2014 New trial record